Thursday, September 08, 2022 3:01:39 PM
Entropic_Squirrel,
Glad you didn’t rethink your post. As you know, I am pretty bold with regard to the meaning of the missing 17 SOC/placebo patients which pseudoprogression alone does not address but enrollment to the point statistically necessary does. That reason might be a really good reason to have accumulated 10,000,000 shares and is a reason the bears never have had a good answer for. The trial data shared to date supports a halt done for positive “good news turned to bad” reasons and I suspect the rational for enrollment only to the point “statistically necessary” will be explained soon enough. I also suspect that all the more recent warning activity on this board and time lines being suggested for expected announcements will garner increased volume from investors gobbling up all they can before Thanksgiving with the realization that there will be good news before the ASM is scheduled. Best wishes.
Glad you didn’t rethink your post. As you know, I am pretty bold with regard to the meaning of the missing 17 SOC/placebo patients which pseudoprogression alone does not address but enrollment to the point statistically necessary does. That reason might be a really good reason to have accumulated 10,000,000 shares and is a reason the bears never have had a good answer for. The trial data shared to date supports a halt done for positive “good news turned to bad” reasons and I suspect the rational for enrollment only to the point “statistically necessary” will be explained soon enough. I also suspect that all the more recent warning activity on this board and time lines being suggested for expected announcements will garner increased volume from investors gobbling up all they can before Thanksgiving with the realization that there will be good news before the ASM is scheduled. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
